Skip to main content

Table 1 The recurrently differentially expressed genes between matched primary tumors and PVTTs

From: Integrative molecular analysis of metastatic hepatocellular carcinoma

GeneFunctionPvTFreqFDREdgeROSVI
DCN Down11< 1e-05No01
CYP2E1Xenobiotics metabolismDown88.75E-05No11
LUM Down88.75E-05No01
TNCFocal adhesionUp8< 1e-05No00
TATAA metabolismDown88.75E-05No23
LAMA2Focal adhesionDown88.75E-05Yes01
SFRP4 Down88.75E-05No00
CPS1AA metabolismDown88.75E-05No13
CYP3A4Xenobiotics metabolismDown88.75E-05No13
IGJ Down71.44E-03No01
CYP2C8Xenobiotics metabolismDown71.44E-03No03
CYP1B1Xenobiotics metabolismDown71.44E-03Yes00
COLEC11 Down71.44E-03No01
IGLL5 Down71.44E-03Yes00
ASPN Down71.44E-03No00
PDGFRAFocal adhesionDown71.44E-03No01
ACTG2 Up73.00E-04Yes00
INHBA Down71.44E-03No00
HPDAA metabolismDown71.44E-03No11
LAMC3Focal adhesionDown71.44E-03Yes01
  1. “PvT” denotes the direction of the differential expressions by comparing PVTTs to primary tumors; “Freq” denotes the number of patients with differentially expressed genes; “FDR” denotes the one-sided FDR calculated by permutation test; “EdgeR” denotes whether the gene is detected by EdgeR differential analysis (paired test, q-value < 0.1); “OS” denotes the number of datasets (two cohorts in total) in which the gene is significantly associated with overall survivals (KM test, p-value < 0.05); and, “VI” denotes the number of datasets (three cohorts in total) in which the gene is significantly associated with vascular invasion (ANOVA test, p-value < 0.05)